hypertonic saline mixed with dextran
Druga single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
Other names: RescueFlow BioPhausia AB, Stockholm Sweden
NCT Number: NCT00878631
This clinical trial will evaluate the ease of conducting a randomized trial on patients with severe head injury who are cared for by paramedics in the out of hospital setting. The trial will compare two different kinds of fluids that are commonly used to elevate blood pressure and minimize the impact of the brain injury. The two solutions are a salt solution of different concentrations. One is a normal saline solution similar to the consistency of human blood and the other is a higher concentration mixed with a sugar that helps to keep the solution in the blood stream longer. This study is conducted without patient consent at the time of the study enrolment. The study will report on whether this trial is feasible in the out of hospital setting before launching into a larger definitive trial.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Phase 2 / Phase 3
St Michael's Hospital, Toronto, Ontario, Canada
The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) is a randomized, placebo-controlled out of hospital trial of blunt trauma patients with head injuries. The study compares a group receiving normal saline according to a paramedic's protocol, with a treatment group receiving a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 (RescueFlow BioPhausia AB, Stockholm Sweden).
The primary objective of this study is to report feasibility in accordance with the methodology described by Lancaster and Dodds*, specifically addressing:
The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.
*Lancaster, G.A., S. Dodd, and P.R. Williamson, Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract, 2004. 10(2): p. 307-12.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
Other names: RescueFlow BioPhausia AB, Stockholm Sweden
250 ccs of normal saline infused within 4 hours of the accident
Time frame: survival at 48 hours, hospital discharge, 30 days and 4 months
Time frame: duration of enrolment
Time frame: duration of study
Time frame: duration of study
Time frame: discharge and at 4 months post incident
Time frame: at 4 and 12 months post incident
Time frame: 4 months post incident
Time frame: samples taken within 48 hours of incident
Unity Health Toronto
Other
The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial
Acronym: TOPHR HIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04242602
Brain Diseases, Brain Injuries
Dallas, Texas, United States
View Trial DetailsNCT04925453
Attention Concentration Difficulty, Attention Impaired
San Diego, California, United States
View Trial DetailsNCT03539848
Brain Concussion, Brain Diseases
Miami, Florida, United States
View Trial DetailsNCT05629169
Brain Concussion, Brain Diseases
New York, United States
View Trial Details